Immunocore Reports Target Enrollment Reached in Phase 3 TEBE‑AM Trial

What Happened
Immunocore Holdings plc filed a Form 8-K on September 14, 2026 (Item 7.01, Regulation FD Disclosure) announcing that it has achieved target patient enrollment in its Phase 3 TEBE‑AM clinical trial. The trial is evaluating tebentafusp as monotherapy and in combination with pembrolizumab for HLA‑A*02:01‑positive patients with unresectable or metastatic melanoma whose disease progressed after prior therapy. A press release describing the milestone was attached as Exhibit 99.1 to the filing.

Key Details

• Filing date: September 14, 2026 (Form 8-K, Item 7.01) with press release attached as Exhibit 99.1.
• Trial: Phase 3 TEBE‑AM evaluating tebentafusp alone and with pembrolizumab.
• Patient population: HLA‑A*02:01‑positive, unresectable or metastatic melanoma, post‑prior therapy.
• Filing signed by CEO Bahija Jallal, Ph.D.

Why It Matters
Reaching target enrollment is a major development milestone for a Phase 3 study: it enables continued progress toward completing the trial, analyzing results, and pursuing potential regulatory submissions or next steps. For investors, this reduces enrollment-related timing risk for TEBE‑AM and signals program advancement; the filing does not include trial results, financial data, or new regulatory decisions.